The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma (Q38944495)

7 September 2017

The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma (English)

1 reference

7 September 2017

2

1 reference

7 September 2017

Ganesh Umapathy

1

0 references

Louis Chesler

object named as

Louis Chesler

4

0 references

Ruth Palmer

12

object named as

Ruth H Palmer

1 reference

7 September 2017

13

Bengt Hallberg

1 reference

7 September 2017

7

Nathanael S Gray

1 reference

7 September 2017

10

Kristina Ruuth

1 reference

7 September 2017

Barbara Witek

3

1 reference

7 September 2017

Laura Danielson

5

1 reference

7 September 2017

Xianming Deng

6

1 reference

7 September 2017

Mikael Johansson

8

1 reference

7 September 2017

Samuel Kvarnbrink

9

1 reference

7 September 2017

Christina Schönherr

11

1 reference

7 September 2017

28 October 2014

1 reference

7 September 2017

1 reference

7 September 2017

7

1 reference

7 September 2017

349

1 reference

7 September 2017

ra102

1 reference

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma

7 September 2017

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

ALK and NSCLC: Targeted therapy with ALK inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

Oncogenic mutations of ALK kinase in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

Activating mutations in ALK provide a therapeutic target in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

Identification of ALK as a major familial neuroblastoma predisposition gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

Neuroblastoma: developmental biology, cancer genomics and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

ArrayCGH-based classification of neuroblastoma into genomic subgroups

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

Unequivocal delineation of clinicogenetic subgroups and development of a new model for improved outcome prediction in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

Phosphoproteomic analysis of anaplastic lymphoma kinase (ALK) downstream signaling pathways identifies signal transducer and activator of transcription 3 as a functional target of activated ALK in neuroblastoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

Primary structure of BMK1: a new mammalian map kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

Components of a new human protein kinase signal transduction pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

ERK5: structure, regulation and function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

The unique C-terminal tail of the mitogen-activated protein kinase ERK5 regulates its activation and nuclear shuttling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

MAPK signalling: ERK5 versus ERK1/2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

ERK5 is a novel type of mitogen-activated protein kinase containing a transcriptional activation domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

Docking interactions in the mitogen-activated protein kinase cascades

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

Molecular cloning of mouse ERK5/BMK1 splice variants and characterization of ERK5 functional domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

MEKK3 directly regulates MEK5 activity as part of the big mitogen-activated protein kinase 1 (BMK1) signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

MEK kinase 2 and the adaptor protein Lad regulate extracellular signal-regulated kinase 5 activation by epidermal growth factor via Src

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

Knockout of ERK5 causes multiple defects in placental and embryonic development

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

Targeted deletion of BMK1/ERK5 in adult mice perturbs vascular integrity and leads to endothelial failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

Anaplastic Lymphoma Kinase (ALK) regulates initiation of transcription of MYCN in neuroblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

Characterization of rearrangements involving the ALK gene reveals a novel truncated form associated with tumor aggressiveness in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

Combined 24-color karyotyping and comparative genomic hybridization analysis indicates predominant rearrangements of early replicating chromosome regions in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

Myc proteins as therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

Discovery of 3,5-Diamino-1,2,4-triazole Ureas as Potent Anaplastic Lymphoma Kinase Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

Role of phosphoinositide 3-kinase in activation of ras and mitogen-activated protein kinase by epidermal growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

Role of the BMK1/ERK5 signaling pathway: lessons from knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

Molecular basis for the substrate specificity of protein kinase B; comparison with MAPKAP kinase-1 and p70 S6 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

Regulation of nuclear translocation of extracellular signal-regulated kinase 5 by active nuclear import and export mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

Targeted expression of MYCN causes neuroblastoma in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

Activated ALK collaborates with MYCN in neuroblastoma pathogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

New strategies in neuroblastoma: Therapeutic targeting of MYCN and ALK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

The genetic landscape of high-risk neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

Emergence of new ALK mutations at relapse of neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

Anaplastic lymphoma kinase activates the small GTPase Rap1 via the Rap1-specific GEF C3G in both neuroblastoma and PC12 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

Synergy study of the inhibitory potential of red wine polyphenols on vascular smooth muscle cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCISIGNAL.2005470

10.1126/SCISIGNAL.2005470

21 January 2018

Identifiers

DOI

1 reference

7 September 2017

1 reference